MedTrace Logo

Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients

NCT04930224 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-06-23

No results posted yet for this study

Summary

Observational, comparative, cross-sectional study

Conditions

Interventions

DIAGNOSTIC_TEST

The effect of GPER-1 on the formation of diabetic retinopathy

Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Sponsors & Collaborators

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Principal Investigators

  • Abdullah Beyoğlu, MD · Kahramanmaras Sutcu Imam University

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-01-31
Completion
2020-04-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930224 on ClinicalTrials.gov